Department of Hematology, Tianjin Medical University General Hospital, Tianjin, 300052, P. R. China.
State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Bioactive, Materials, Ministry of Education and College of Life Sciences, Nankai University, Tianjin, 300071, P. R. China.
Adv Sci (Weinh). 2023 May;10(13):e2207475. doi: 10.1002/advs.202207475. Epub 2023 Feb 23.
Although the curative effect of hematological malignancies has been improved in recent years, relapse or drug resistance of hematological malignancies will eventually recur. Furthermore, the microenvironment disorder is an important mechanism in the pathogenesis of hematological malignancies. Immunogenic cell death (ICD) is a unique mechanism of regulated cell death (RCD) that triggers an intact antigen-specific adaptive immune response by firing a set of danger signals or damage-associated molecular patterns (DAMPs), which is an immunotherapeutic modality with the potential for the treatment of hematological malignancies. This review summarizes the existing knowledge about the induction of ICD in hematological malignancies and the current research on combining ICD inducers with other treatment strategies for hematological malignancies.
虽然近年来血液系统恶性肿瘤的疗效有所提高，但血液系统恶性肿瘤最终仍会复发或产生耐药性。此外，微环境紊乱是血液系统恶性肿瘤发病机制中的一个重要机制。免疫原性细胞死亡（ICD）是一种独特的调控性细胞死亡（RCD）机制，通过释放一组危险信号或损伤相关分子模式（DAMPs）来触发完整的抗原特异性适应性免疫反应，这是一种具有治疗血液系统恶性肿瘤潜力的免疫治疗方式。本文综述了血液系统恶性肿瘤中诱导 ICD 的现有知识以及将 ICD 诱导剂与血液系统恶性肿瘤的其他治疗策略相结合的研究现状。
